Antihypertensive bicyclo compounds

InformationNintedanib (BIBF 1120, Intedanib, Vargatef, Ofev) is a potent triple angiokinase inhibitor forVEGFR1/2/3,FGFR1/2/3andPDGFRα/βwithIC50of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM in cell-free assays. Phase 3.In vitroBIBF1120

RMC-6272 (RM-006) is a bi-steric mTORC1 -selective inhibitor. RMC-6272 exhibits potent and selective (&gt: 10-fold) inhibition of mTORC1 over mTORC2. RMC-6272 shows improved inhibition of mTORC1 in comparison to Rapamycin, and induces more cell

Roscovitine (Seliciclib, CYC202) is a potent and selective CDK inhibitor for Cdc2, CDK2 and CDK5 with IC50 of 0.65 μM, 0.7 μM and 0.16 μM. It shows little effect on CDK4/6. Phase 2.A potent and selective inhibitor of cyclin-dependent kinases.

Roscovitine (Seliciclib, CYC202) is a potent and selective CDK inhibitor for Cdc2, CDK2 and CDK5 with IC50 of 0.65 μM, 0.7 μM and 0.16 μM. It shows little effect on CDK4/6. Phase 2.A potent and selective inhibitor of cyclin-dependent kinases.

Application SD-208 was used to inhibit the activity of ALK5 kinase in bovine retinal vascular cells. 2 Biochem/physiol Actions SD-208 is TGF-&#946:R I kinase inhibitor with IC 50 =49 nM based on direct enzymatic assay of TGFRI kinase (ALK5)

Application SD-208 was used to inhibit the activity of ALK5 kinase in bovine retinal vascular cells. 2 Biochem/physiol Actions SD-208 is TGF-&#946:R I kinase inhibitor with IC 50 =49 nM based on direct enzymatic assay of TGFRI kinase (ALK5)

SnAP (Sn amino protocol) reagents have been developed by Professor Dr. Jeffrey Bode and co-workers.

TLR7/8 agonist 1 is a toll-like receptor ( TLR7 )/ TLR8 dual-agonistic imidazoquinoline.In VitroTLR7/8 agonist 1 (Compound 5d) shows prominent immunostimulatory activities. TLR7/8 agonist 1 serves as a convenient precursor for the covalent

TLR7/8 agonist 1 is a toll-like receptor ( TLR7 )/ TLR8 dual-agonistic imidazoquinoline.In VitroTLR7/8 agonist 1 (Compound 5d) shows prominent immunostimulatory activities. TLR7/8 agonist 1 serves as a convenient precursor for the covalent

TLR7/8 agonist 1 is a toll-like receptor ( TLR7 )/ TLR8 dual-agonistic imidazoquinoline.In VitroTLR7/8 agonist 1 (Compound 5d) shows prominent immunostimulatory activities. TLR7/8 agonist 1 serves as a convenient precursor for the covalent

TLR7/8 agonist 1 is a toll-like receptor ( TLR7 )/ TLR8 dual-agonistic imidazoquinoline.In VitroTLR7/8 agonist 1 (Compound 5d) shows prominent immunostimulatory activities. TLR7/8 agonist 1 serves as a convenient precursor for the covalent

TLR7/8 agonist 1 is a toll-like receptor ( TLR7 )/ TLR8 dual-agonistic imidazoquinoline.In VitroTLR7/8 agonist 1 (Compound 5d) shows prominent immunostimulatory activities. TLR7/8 agonist 1 serves as a convenient precursor for the covalent